SCN1A and epilepsy: Identified in five DS and GEFS+ cases, this mechanism not only validates non-coding variants as disruptors of core RNA processing machinery but also highlights splicing regulatory elements as potential therapeutic targets for SCN1A-related epilepsies (Carvill et al., 2018).